Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Case Reports
Share your love
Novel AI Boosts Geographic Atrophy Clinical Trial Efficiency
A new artificial intelligence (AI) system developed by researchers from UCL and Moorfields Eye Hospital could potentially revolutionize the recruitment process for clinical trials aimed at treating Geographic Atrophy (GA), an advanced form of dry age-related macular degeneration (AMD) that…
NVISION Eye Centers Partners with Parkhurst NuVision
NVISION Eye Centers, a prominent provider of eye care services nationwide, announced a strategic collaboration with Parkhurst NuVision of San Antonio, Texas, through its subsidiary NVision Clinical Research, LLC. This partnership aims to advance clinical trials in ophthalmology drug development,…
Notal Vision’s OCT Promises Advances in Wet AMD Management
Notal Vision announced findings from a pioneering clinical trial using home-based optical coherence tomography (OCT) to oversee patients with wet age-related macular degeneration (AMD). Published in Retina, the results highlighted a notable reduction in office visits and treatment frequency, while…
4DMT Receives FDA Clearance of IND for GA Treatment
4D Molecular Therapeutics (4DMT) announced the FDA clearance of its investigational new drug application (IND) for 4D-175, an R100 vector-based intravitreal genetic medicine intended for treating geographic atrophy (GA) in patients. Phase 1 GAZE Clinical Trial Details The phase 1…
Novartis’ AMD Drug Linked to Rare Retinal Side Effects
Two recent studies have found that a drug called brolucizumab, which was approved in 2019 and developed by Swiss pharmaceutical company Novartis AG to treat wet age-related macular degeneration (AMD), can cause rare retinal side effects due to its interaction…
Primary Open Angle Glaucoma (POAG)
A subtype of glaucomas known as primary open angle glaucoma (POAG) is characterized by an open, seemingly normal anterior chamber angle and elevated intraocular pressure (IOP), with no additional underlying disease. Secondary glaucoma is a condition where the elevated IOP…
FDA Grants Breakthrough and RMAT Status to Aurion’s AURN001
Aurion Biotech has been granted Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) Designation by the FDA for AURN001, Aurion’s innovative allogeneic cell therapy candidate designed to treat corneal edema secondary to corneal endothelial disease. Expediting Development and…
Metformin Found Ineffective Against Geographic Atrophy
In the quest to find effective treatments for eye diseases, the METformin for the MINimization of Geographic Atrophy Progression (METforMIN) trial sought to evaluate the efficacy of oral metformin in slowing the progression of geographic atrophy (GA) and its effects…
Teprotumumab Shows Long-Lasting Benefits for TED Patients
Research presented at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Massachusetts, and published in the journal Thyroid, indicates that most patients with thyroid eye disease (TED) treated with teprotumumab did not require additional treatments nearly two years later.…
Beacon Therapeutics Initiates VISTA Trial for X-Linked RP
Beacon Therapeutics announced the treatment of the inaugural patient in its pivotal VISTA clinical trial with its lead asset, AGTC-501 (laruparetigene zovaparvovec), marking a significant advancement in the pursuit of combating X-Linked Retinitis Pigmentosa (XLRP). Objective of the VISTA Trial…